Viewing nowEmpagliflozin 25 mg tablet (Enpyangjeong)
Empagliflozin 25mg
Tablet · Prescription medication
Daehan New Pharm Co., Ltd.

MFDS item code 202102113 · Approved 2021.03.05 · Insurance code 669908480
Improvement of glycemic control in adults with type 2 diabetes
This medication is used together with dietary and exercise therapy to help control blood sugar in adults with type 2 diabetes. It can be used as monotherapy, but if blood sugar control is difficult, other diabetes medications such as metformin, pioglitazone, sulfonylureas, insulin, or DPP-4 inhibitors like linagliptin can be administered in combination. In particular, for patients with type 2 diabetes who have cardiovascular diseases, caution regarding cardiovascular events is necessary, and consulting a specialist for clinical trial information is recommended. This medication improves blood sugar control and supports diabetes management.
The recommended dose of this medicine is 10 mg once daily, whether used as monotherapy or as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this medicine is well tolerated and additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions, 3. Adverse Reactions). This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take a double dose in one day. Special populations •Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well and whose glomerular filtration rate remains < 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. This medicine should be discontinued if the glomerular filtration rate decreases to < 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those on dialysis, because efficacy is not expected. •Patients with hepatic impairment No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. •Older patients No dose adjustment based on age is necessary. Renal function and the risk of volume depletion should be considered in patients aged 75 years or older. Initiation of treatment with this medicine is not recommended in patients aged 85 years or older because clinical experience is limited (see Precautions, 4. General Precautions).
This medication should not be used in certain patients. First, patients with allergic reactions to the active ingredient or any of the components should not take this drug. Second, this drug is not suitable for patients with type 1 diabetes or diabetic ketoacidosis. Third, it should not be administered to patients with significantly impaired kidney function, specifically those with a glomerular filtration rate below 30 mL/min/1.73m² or patients with end-stage renal disease or those on dialysis. Fourth, this drug contains lactose; hence, patients with lactose intolerance, galactose intolerance, or hereditary lactose enzyme deficiency must not use it. Furthermore, it should be used with caution in patients with somewhat impaired kidney function, and it is advisable not to initiate treatment if the glomerular filtration rate is below 60 mL/min/1.73m². If the glomerular filtration rate falls below 45 mL/min/1.73m² during treatment, the administration should be stopped. In patients with end-stage renal disease or those on dialysis, the efficacy of this medication is not expected, so it should not be used. In patients with heart failure, it should be administered with caution in NYHA class I-II, and it is not recommended for those in class III-IV. There is an increased risk of hypoglycemia when used with insulin or sulfonylureas, so in such cases, it may be necessary to adjust the dosage of insulin or sulfonylureas. Possible adverse reactions that may occur while using this medication include hypoglycemia, genital infections (vulvovaginitis, vulvar inflammation, glans inflammation, etc.), increased urination, urinary tract infections, decreased fluid volume, etc. Particularly, hypoglycemia may occur more frequently when combined with insulin or sulfonylureas, so caution should be exercised. Also, blood tests may temporarily show an increase in serum creatinine or a decrease in glomerular filtration rate, but these usually resolve after discontinuing treatment. Rarely, a serious metabolic abnormality known as ketoacidosis may occur; therefore, if symptoms such as vomiting, abdominal pain, or breathing difficulties arise, immediate consultation with a physician is necessary. This medication is not recommended for pregnant women, and if pregnancy is confirmed, it should be discontinued. While breastfeeding, it is also advisable to avoid using this medication and to discontinue breastfeeding during treatment. This medication has not been shown to be safe and effective in children under 18 years of age and should not be used in this population. No specific toxic symptoms have been reported in case of overdose, but appropriate treatment according to the patient's condition is necessary in the event of excessive intake. Finally, this medication should be stored out of reach of children, and care should be taken not to transfer it to other containers as this may affect quality.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent exposure to air or moisture, preferably at room temperature between 1°C and 30°C. Avoid direct sunlight and high temperatures, and keep it out of the reach of children.
Pale yellow, biconvex, oval film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowEmpagliflozin 25mg
Tablet · Prescription medication
Daehan New Pharm Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Korea Prime Pharmaceuticals Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.